CorMedix expects Q1 sales above estimates, lifts H1 outlook

 

• CorMedix (NASDAQ:CRMD) expects preliminary net revenue of $39M (consensus estimate: $32.2M) and adjusted EBITDA to exceed $22.5M for the first quarter of 2025.
• Since providing initial guidance, the company received larger than expected orders during the final week of March, and has also obtained additional visibility into inventory levels on hand at some of our current purchasing customers. Based on this, CorMedix has lifted its H1 for net sales to existing purchasing customers to a revised range of $62M to $70M.
• For Q2, the company currently expects net sales from existing purchasing customers to be lower than that in Q1 due to the timing of shipments to those customers between quarters. This does not suggest an anticipated decrease in patient utilization in the second quarter or the second half of 2025, the company said.
• Shares of CorMedix (NASDAQ:CRMD) gained nearly 16% premarket on Tuesday.

https://www.msn.com/en-us/money/taxes/cormedix-expects-q1-sales-above-estimates-lifts-h1-outlook/ar-AA1Cwqn8